Aspire Biopharma Holdings (ASBP)
NASDAQ:ASBP
Total Valuation
Aspire Biopharma Holdings has a market cap or net worth of $7.16M. The enterprise value is -$4.72M.
Market Cap$7.16M
Enterprise Value-$4.72M
Share Statistics
Aspire Biopharma Holdings has 1,295,234 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,295,234
Owned by Insiders1.54%
Owned by Institutions―
Financial Efficiency
Aspire Biopharma Holdings’s return on equity (ROE) is 3.84 and return on invested capital (ROIC) is 395.26%.
Return on Equity (ROE)3.84
Return on Assets (ROA)-18.66
Return on Invested Capital (ROIC)395.26%
Return on Capital Employed (ROCE)3.08
Revenue Per Employee3.10K
Profits Per Employee-12.24M
Employee Count2
Asset Turnover<0.01
Inventory Turnover0.02
Valuation Ratios
The current PE Ratio of Aspire Biopharma Holdings is ―. Aspire Biopharma Holdings’s PEG ratio is 0.98.
PE Ratio―
PS Ratio38181.40
PB Ratio-37.14
Price to Fair Value-37.14
Price to FCF-48.10
Price to Operating Cash Flow-0.14
PEG Ratio0.98
Income Statement
In the last 12 months, Aspire Biopharma Holdings had revenue of 6.20K and earned -24.48M in profits. Earnings per share was -16.38.
Revenue6.20K
Gross Profit-116.00
Operating Income-19.35M
Pretax Income-24.48M
Net Income-24.48M
EBITDA-19.35M
Earnings Per Share (EPS)-16.38
Cash Flow
In the last 12 months, operating cash flow was -6.21M and capital expenditures 0.00, giving a free cash flow of -6.21M billion.
Operating Cash Flow-6.21M
Free Cash Flow-6.21M
Free Cash Flow per Share-4.79
Dividends & Yields
Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-98.81%
50-Day Moving Average14.91
200-Day Moving Average193.09
Relative Strength Index (RSI)37.08
Average Volume (3m)27.58M
Important Dates
Aspire Biopharma Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Aspire Biopharma Holdings as a current ratio of 0.17, with Debt / Equity ratio of 12.90%
Current Ratio0.17
Quick Ratio0.14
Debt to Market Cap<0.01
Net Debt to EBITDA-0.02
Interest Coverage Ratio-2.27
Taxes
In the past 12 months, Aspire Biopharma Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aspire Biopharma Holdings EV to EBITDA ratio is -12.26, with an EV/FCF ratio of -48.17.
EV to Sales38.24K
EV to EBITDA-12.26
EV to Free Cash Flow-48.17
EV to Operating Cash Flow-48.17
Balance Sheet
Aspire Biopharma Holdings has $5.86M in cash and marketable securities with $499.21K in debt, giving a net cash position of $5.36M billion.
Cash & Marketable Securities$5.86M
Total Debt$499.21K
Net Cash$5.36M
Net Cash Per Share$4.14
Tangible Book Value Per Share-$4.27
Margins
Gross margin is 16.30%, with operating margin of -312016.95%, and net profit margin of -394725.06%.
Gross Margin16.30%
Operating Margin-312016.95%
Pretax Margin-394725.06%
Net Profit Margin-394725.06%
EBITDA Margin-312016.95%
EBIT Margin-312016.95%
Analyst Forecast
The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast92.52%